

Demethylating Agent Azacitidine on Prevention of Acute Kidney Injury-chronic Kidney Disease Continuum

NCT05325099

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	National Taiwan University Hospital
Enrollment	60 participants

Plain Language Summary

This study tests whether azacitidine (a demethylating drug used in blood cancer treatment) can prevent acute kidney injury (AKI) in patients receiving certain cancer treatments that commonly damage the kidneys.

****You may be eligible if...****

- You are receiving a cancer treatment known to carry a risk of acute kidney injury
- You are 18 or older
- Your baseline kidney function meets study requirements
- You consent to participate

****You may NOT be eligible if...****

- You already have severe chronic kidney disease
- You are pregnant or breastfeeding
- You have allergies to azacitidine or its components
- You have an active serious infection

Talk to your doctor to see if this trial is right for you.

Key Eligibility Criteria

Inclusion (1)

- Patient with cardiac surgery associated-AKI, stage 2 and stage 3

Exclusion (9)

- Chronic kidney disease
- Decompensated heart failure (EF < 45%)
- Liver cirrhosis, child B or C
- Acute infection
- Acute bleeding

... and 4 more (see full listing online)

Locations (1 total)

Yu Hsiang Chou, Taipei, Taiwan

<https://clinicaltrials.gov/study/NCT05325099>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).